Apollo Therapeutics
Generated by Meeveem AI
"Translating breakthrough biology from world-leading universities into novel therapeutics"
Cambridge
•51 - 250 Employees
•Biotechnology
About Apollo Therapeutics
Apollo Therapeutics translates breakthroughs in biology and basic medical research from six world-leading universities into innovative new medicines. The company operates a portfolio biopharmaceutical model, building a diversified pipeline of over 20 therapeutic programs with uncorrelated risk across oncology, immunology, and metabolic disease. The portfolio model centres on highly seasoned drug discoverers and developers recruited from major pharmaceutical companies. Apollo in-licenses clinical-stage programs where unique insights exist from its discovery activities. Backed by Patient Square Capital and Rock Springs Capital, Apollo operates from Cambridge, Oxford, Boston, and Chicago.
61
Team Members
2016
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A future where fundamental medical breakthroughs from the world's leading universities are systematically translated into transformative medicines that change the standard of care for serious diseases.
Our Mission
Translates fundamental medical research and breakthrough biology into innovative new medicines through a scalable portfolio model partnered with world-leading universities.